通过时间-杀菌曲线法评估LY333328、万古霉素、替考拉宁、氨苄西林-舒巴坦、曲伐沙星和RP59500单独或与利福平或庆大霉素联合使用对不同株万古霉素中介金黄色葡萄球菌的杀菌活性。
Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
作者信息
Hershberger E, Aeschlimann J R, Moldovan T, Rybak M J
机构信息
Department of Pharmacy Services, Detroit Receiving Hospital, Michigan 48201, USA.
出版信息
Antimicrob Agents Chemother. 1999 Mar;43(3):717-21. doi: 10.1128/AAC.43.3.717.
Abstract
This in vitro study evaluated the activities of vancomycin, LY333328, and teicoplanin alone and in combination with gentamicin, rifampin, and RP59500 against Staphylococcus aureus isolates with intermediate susceptibilities to vancomycin. Ampicillin-sulbactam and trovafloxacin were also evaluated. LY333328 and ampicillin-sulbactam resulted in bactericidal activity against all isolates. The combination of gentamicin with glycopeptides showed synergistic activity, while rifampin had no added benefit.
摘要
这项体外研究评估了万古霉素、LY333328和替考拉宁单独使用以及与庆大霉素、利福平、RP59500联合使用对万古霉素中度敏感的金黄色葡萄球菌分离株的活性。还评估了氨苄西林-舒巴坦和曲伐沙星。LY333328和氨苄西林-舒巴坦对所有分离株均具有杀菌活性。庆大霉素与糖肽类联合使用显示出协同活性，而利福平并无额外益处。
相似文献
1
Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
Antimicrob Agents Chemother. 1999 Mar;43(3):717-21. doi: 10.1128/AAC.43.3.717.
2
In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
Diagn Microbiol Infect Dis. 1997 Dec;29(4):233-9. doi: 10.1016/s0732-8893(97)00161-2.
3
Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Antimicrob Agents Chemother. 2000 May;44(5):1153-8. doi: 10.1128/AAC.44.5.1153-1158.2000.
4
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Antimicrob Agents Chemother. 2000 Nov;44(11):2991-8. doi: 10.1128/AAC.44.11.2991-2998.2000.
5
Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 1998 Oct;42(10):2564-8. doi: 10.1128/AAC.42.10.2564.
6
Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria.
J Antimicrob Chemother. 1997 Mar;39(3):405-9. doi: 10.1093/jac/39.3.405.
7
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
Antimicrob Agents Chemother. 1997 Jun;41(6):1307-12. doi: 10.1128/AAC.41.6.1307.
8
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Antimicrob Agents Chemother. 1997 Oct;41(10):2165-72. doi: 10.1128/AAC.41.10.2165.
9
Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
J Antimicrob Chemother. 1998 Feb;41(2):273-6. doi: 10.1093/jac/41.2.273.
10
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
Antimicrob Agents Chemother. 1996 Oct;40(10):2416-9. doi: 10.1128/AAC.40.10.2416.
引用本文的文献
1
Culture negative sepsis: a national survey of variations in clinical practice.
J Perinatol. 2024 Dec;44(12):1805-1806. doi: 10.1038/s41372-024-02140-w. Epub 2024 Oct 18.
2
New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0261420. doi: 10.1128/aac.02614-20. Epub 2022 Apr 27.
3
Antimicrobial activity of essential oils against multidrug-resistant clinical isolates of the Burkholderia cepacia complex.
PLoS One. 2018 Aug 2;13(8):e0201835. doi: 10.1371/journal.pone.0201835. eCollection 2018.
4
Probing the Mechanism of LAL-32, a Gold Nanoparticle-Based Antibiotic Discovered through Small Molecule Variable Ligand Display.
Bioconjug Chem. 2017 Jul 19;28(7):1807-1810. doi: 10.1021/acs.bioconjchem.7b00199. Epub 2017 Jun 27.
5
Oritavancin diphosphate.
Hosp Pharm. 2014 Dec;49(11):1049-60. doi: 10.1310/hpj4911-1049.
6
Release of gentamicin and vancomycin from preformed spacers in infected total hip arthroplasties: measurement of concentrations and inhibitory activity in patients' drainage fluids and serum.
ScientificWorldJournal. 2013 Sep 22;2013:752184. doi: 10.1155/2013/752184. eCollection 2013.
7
An approach to identifying drug resistance associated mutations in bacterial strains.
BMC Genomics. 2012;13 Suppl 7(Suppl 7):S23. doi: 10.1186/1471-2164-13-S7-S23. Epub 2012 Dec 13.
8
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.
Antimicrob Agents Chemother. 2008 Oct;52(10):3820-2. doi: 10.1128/AAC.00361-08. Epub 2008 Jul 21.
9
Vancomycin for the treatment of methicillin-resistant staphylococcal and enterococcal infections in 15 horses.
Can J Vet Res. 2005 Oct;69(4):278-86.
10
Glycopeptide antibiotics: from conventional molecules to new derivatives.
Drugs. 2004;64(9):913-36. doi: 10.2165/00003495-200464090-00001.
本文引用的文献
1
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
J Antimicrob Chemother. 1997 Jul;40(1):135-6. doi: 10.1093/jac/40.1.135.
2
Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin.
J Antimicrob Chemother. 1997 Jun;39 Suppl B:75-80. doi: 10.1093/jac/39.suppl_2.75.
3
Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996.
MMWR Morb Mortal Wkly Rep. 1997 Jul 11;46(27):624-6.
4
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.
Antimicrob Agents Chemother. 1996 Mar;40(3):701-5. doi: 10.1128/AAC.40.3.701.
5
Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 1996 Jun;40(6):1534-5. doi: 10.1128/AAC.40.6.1534.
6
Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus.
Antimicrob Agents Chemother. 1986 Apr;29(4):611-3. doi: 10.1128/AAC.29.4.611.
Zotero 插件